Current issue
About the Journal
Scientific Council
Editorial Board
Regulatory and archival policy
Code of publishing ethics
Publisher
Information about the processing of personal data in relation to cookies and newsletter subscription
Archive
For Authors
For Reviewers
Contact
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Links
Sklep Wydawnictwa SUM
Biblioteka Główna SUM
Śląski Uniwersytet Medyczny w Katowicach
Privacy policy
Accessibility statement
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Treatment of unipolar affective disorders in pregnant women – benefits and risks
1
Zespół Opieki Zdrowotnej w Nysie / Health Care Team in Nysa, Poland
2
Wojewódzki Szpital Specjalistyczny nr 5 im. św. Barbary w Sosnowcu / St. Barbara Provincial Specialist Hospital No. 5 in Sosnowiec, Poland
3
Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA im. Sierżanta Grzegorza Załogi w Katowicach / Sergeant Grzegorz Załoga Independent Public Health Care Institute of the Ministry of Internal Affairs and Administration in Katowice, Poland
Corresponding author
Ann. Acad. Med. Siles. 2024;78:204-209
KEYWORDS
TOPICS
ABSTRACT
Mental disorders are becoming an increasingly common health condition in society worldwide, significantly affecting pregnant women as well. According to the latest research, 1.5 million people in Poland and as many as 350 million people worldwide suffer from depression. It has also been established that the problem affects as much as 10.5% of women across Europe. An increased risk of developing affective disorders is noted in the age group between 18 and 44 years, which is the population of women of reproductive age. The medical community faces the dilemma of implementing treatment that ensures the safety of the child during medication intake, while also considering the consequences of discontinuing treatment related to withdrawal effects of psychotropic substances and the potential for relapse of symptoms in women. The aim of the study was to review and summarize methods of treating depressive disorders in pregnant women, as well as to assess the benefits and risks associated with undertaking various therapeutic treatments.
A review of scientific publications published in English and Polish was conducted using the PubMed and Google Scholar databases. Keywords such as “depression” and “pregnancy” were used. The treatment of depressive disorders in pregnant women remains a controversial topic and requires an individualized approach to each patient. During therapy, the potential benefits of pharmacological treatment, which carries the risk of complications for the fetus, and the choice of less invasive non-pharmacological methods should be considered. The diagnostic process and choice of further management should also include the potential risks associated with not treating unipolar affective disorder in pregnant women.
REFERENCES (33)
1.
Bokhari R., Bhatara V.S., Bandettini F., McMillin J.M. Postpartum psychosis and postpartum thyroiditis. Psychoneuroendocrinology 1998; 23(6): 643–650, doi: 10.1016/s0306-4530(98)00034.
2.
Abou-Saleh M.T., Ghubash R. The prevalence of early postpartum psychiatric morbidity in Dubai: a transcultural perspective. Acta Psychiatr. Scand. 1997; 95(5): 428–432, doi: 10.1111/j.1600-0447.1997.tb09657.x.
3.
Janik I., Maciejewska M., Fabian-Danielewska A., Korabiusz K., Wawryków A., Stecko M. Emotional disorders in the perinatal period. J. Educ. Health Sport 2018; 8(9): 983–989, doi: 10.5281/zenodo.1419713.
4.
Steiner M. Postpartum psychiatric disorders. Can. J. Psychiatry 1990; 35(1): 89–95, doi: 10.1177/070674379003500117.
5.
Rybakowski J. Choroby afektywne. W: Psychiatria: podręcznik dla studentów medycyny. M. Jarema, J. Rabe-Jabłońska [red.]. Wyd. 1. Wyd. Lekarskie PZWL. Warszawa 2011, s. 174–183.
6.
Heitzman J., Solak M. Zespół odstawienia po lekach antydepresyjnych – problem dla lekarza i pacjenta. Psychiatr. Pol. 2007; 41(5): 601–613.
7.
Marcus S.M. Depression during pregnancy: rates, risks, and consequences. Can. J. Clin. Pharmacol. 2009; 16(1): e15–22.
8.
Mutschler E., Geisslinger G., Kroemer H.K., Menzel S., Ruth P. Leki wpływające na sferę psychiczną (leki psychotropowe). W: Mutschler farmakologia i toksykologia: podręcznik. M. Droździk, I. Kocić, D. Pawlak [red. wyd. pol.]. Wyd. 4. MedPharm Polska. Wrocław 2016, s. 146–183.
9.
Ritter J.M., Flower R., Henderson G., Loke Y.K., MacEwan D., Rang H.P. Leki przeciwdepresyjne. W: Rang i Dale Farmakologia. D. Mirowska-Guzel, B. Okopień [red. wyd. pol.]. Wyd. 9. Edra Urban & Partner. Wrocław 2021, s. 651–671.
10.
Urban-Kowalczyk M. Leczenie objawów depresyjnych u kobiet w ciąży – opcje terapeutyczne. Psychiatr. Dypl. 2017; 14(1): 23–28.
11.
Hale T.W. Maternal medications during breastfeeding. Clin. Obstet. Gynecol. 2004; 47(3): 696–711, doi: 10.1097/01.grf.0000135653.56778.3f.
12.
Kostowski W. Leki przeciwdepresyjne. W: Farmakologia: podstawy farmakoterapii. T. 2. W. Kostowski, Z.S. Herman [red.]. Wyd. Lekarskie PZWL. Warszawa 2008, s. 133–153.
13.
Smart C., Anderson I.M., McAllister-Williams R.H. Antidepressants and ECT. W: Fundamentals of clinical psychopharmacology. I.M. Anderson, R.H. McAllister-Williams [red.]. 4th ed. CRC Press, Taylor & Francis Group. Boca Raton 2015, s. 77–103.
14.
Davis R.L., Rubanowice D., McPhillips H., Raebel M.A., Andrade S.E., Smith D. i wsp. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medication during pregnancy. Pharmacoepidemiol. Drug Saf. 2007; 16(10): 1086–1094, doi: 10.1002/pds.1462.
15.
Kloos A.L., Dubin-Rhodin A., Sackett J.C., Dixon T.A., Weller R.A, Weller E.B. Wpływ zaburzeń nastroju i ich leczenia na ciężarną, płód i dziecko. Curr. Psychiatry Rep. 2010; 12: 96–103.
16.
Müldner-Nieckowski Ł., Cyranka K., Smiatek-Mazgaj B., Mielimąka M., Sobański J., Rutkowski K. Psychotherapy for pregnant women with psychiatric disorders. Psychiatr. Pol. 2015; 49(1): 49–56, doi: 10.12740/PP/31493.
17.
Cantor Sackett J., Weller R.A., Weller E.B. Selective serotonin reuptake inhibitor use during pregnancy and possible neonatal complications. Curr. Psychiatry Rep. 2009; 11(3): 253–257, doi: 10.1007/s11920-009-0038-5.
18.
Yonkers K.A., Wisner K.L., Stewart D.E., Oberlander T.F., Dell D.L., Stotland N. i wsp. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen. Hosp. Psychiatry 2009; 31(5): 403–413, doi: 10.1016/j.genhosppsych.2009.04.003.
19.
Fukushima N., Nanao K., Fukushima H., Namera A., Miura M. A neonatal prolonged QT syndrome due to maternal use of oral tricyclic antidepressants. Eur. J. Pediatr. 2016; 175(8): 1129–1132, doi: 10.1007/s00431-016-2722-x.
20.
Palmsten K., Huybrechts K.F., Michels K.B., Williams P.L., Mogun H., Setoguchi S. i wsp. Antidepressant use and risk for preeclampsia. Epidemiology 2013; 24(5): 682–691, doi: 10.1097/EDE.0b013e31829e0aaa.
21.
Misztal Z., Pawlicka M., Mroczek A., Bałabuszek K., Kasprzak K., Koziarska-Rościszewska M. Wpływ stosowanych antydepresantów podczas ciąży na rozwój płodu i noworodka. W: Nauki przyrodnicze i medyczne: najnowsze doniesienia dotyczące nauk medycznych i biotechnologicznych. J. Bednarski, M. Bajda [red.]. Instytut Promocji Kultury i Nauki Dr Jerzy Bednarski. Lublin 2018, s. 8–18.
22.
Malhotra N., Malhotra V., Malhotra P., Bhardwaj R. Modified electroconvulsive therapy during pregnancy. J. Anaesth. Clin. Pharmacol. 2008; 24(3): 351–352.
23.
Sanz E.J., De-las-Cuevas C., Kiuru A., Bate A., Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365(9458): 482–487, doi: 10.1016/S0140-6736(05)17865-9.
24.
Reis M., Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol. Med. 2010; 40(10): 1723–1733. doi: 10.1017/s0033291709992194.
25.
Bałkowiec-Iskra E., Mirowska-Guzel D.M., Wielgoś M. Effect of antidepressants use in pregnancy on foetus development and adverse effects in newborns. Ginekol. Pol. 2017; 88(1): 36–42, doi: 10.5603/GP.a2017.0007.
26.
Gentile S. Tricyclic antidepressants in pregnancy and puerperium. Expert Opin. Drug Saf. 2014; 13(2): 207–225, doi: 10.1517/14740338.2014.869582.
27.
Bieńkowski P., Samochowiec J., Sienkiewicz-Jarosz H., Wichniak A., Mastalerz-Migas A. Bezpieczne stosowanie benzodiazepin w podstawowej opiece zdrowotnej – rekomendacje dla lekarzy rodzinnych. Lekarz POZ 2019; 5(3–4): 177–193.
28.
Nayeri U.A. Niepowściągliwe wymioty ciężarnych – postępowanie krok po kroku. Ginekol. Dypl. 2012; 14(5): 61–68.
29.
Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Committee on Drugs. American Academy of Pediatrics. Pediatrics 2000; 105(4 Pt 1): 880–887, doi: 10.1542/peds.105.4.880.
30.
Wang L.H., Lin H.C., Lin C.C., Chen Y.H., Lin H.C. Increased risk of adverse pregnancy outcomes in women receiving zolpidem during pregnancy. Clin. Pharmacol. Ther. 2010; 88(3): 369–374, doi: 10.1038/clpt.2010.97.
31.
Wikner B.N., Källén B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans? J. Clin. Psychopharmacol. 2011; 31(3): 356–359, doi: 10.1097/JCP.0b013e3182197055.
32.
Kasar M., Saatcioglu O., Kutlar T. Electroconvulsive therapy use in pregnancy. J. ECT 2007; 23(3): 183–184, doi: 10.1097/YCT.0b013e318065b12f.
33.
Rymaszewska J., Dolna M., Gryboś M., Kiejna A. Zaburzenia psychiczne okołoporodowe – epidemiologia, etiologia, klasyfikacja, leczenie. Ginekol. Pol. 2005; 76(4): 322–330.
Share
RELATED ARTICLE
| eISSN: | 1734-025X |
The Medical University of Silesia in Katowice, as the Operator of the annales.sum.edu.pl website, processes personal data collected when visiting the website. The function of obtaining information about Users and their behavior is carried out by voluntarily entered information in forms, saving cookies in end devices, as well as by collecting web server logs, which are in the possession of the website Operator. Data, including cookies, are used to provide services in accordance with the Privacy policy.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
